524. Understanding the Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections in the United States (US): Insights from a Survey of Hospital-Based Pharmacists

BACKGROUND: New anti-CRE antibiotics (ceftazidime–avibactam, C-A; meropenem-vaborbactam, M-V; plazomicin, PLZ) are associated with improved outcomes and lower toxicity than polymixins (PMs; colistin; polymyxin B) in treating CRE infections. We previously demonstrated that ~40% (range: 28–71%) and ~2...

Descripción completa

Detalles Bibliográficos
Autores principales: Potoski, Brian, Buehrle, Deanna, Nguyen, Minh-Hong, Clancy, Cornelius J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811047/
http://dx.doi.org/10.1093/ofid/ofz360.593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811047/
http://dx.doi.org/10.1093/ofid/ofz360.593

Ejemplares similares